Ustekinumab-Ttwe (1 brand name, 1 dosage form, 2 routes)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION, SUBCUTANEOUS.
Brand Names
- PYZCHIVA
Contraindications
PYZCHIVA is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in PYZCHIVA [see Warnings and Precautions (5.5)].
Adverse Reactions
The following serious adverse reactions are discussed elsewhere in the label: Infections [see Warnings and Precautions (5.1)] Malignancies [see Warnings and Precautions (5.4)] Serious Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.6)] Noninfectious Pneumonia [see Warnings and Precautions (5.8)]
Overdosage
Single doses up to 6 mg/kg intravenously have been administered in clinical trials without dose-limiting toxicity. In case of overdosage, monitor the patient for any signs or symptoms of adverse reactions or effects and institute appropriate symptomatic treatment immediately. Consider contacting the Poison Help line 1-800-222-1222 or a medical toxicologist for additional overdose management recommendations.